Proteasome Inhibitors Block DNA Repair and Radiosensitize Non-Small Cell Lung Cancer

被引:52
|
作者
Cron, Kyle R. [1 ]
Zhu, Kaya [1 ]
Kushwaha, Deepa S. [1 ]
Hsieh, Grace [1 ]
Merzon, Dmitry [1 ]
Rameseder, Jonathan [2 ]
Chen, Clark C. [3 ]
D'Andrea, Alan D. [1 ,4 ]
Kozono, David [1 ]
机构
[1] Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02115 USA
[2] MIT, Cambridge, MA 02139 USA
[3] Univ Calif San Diego, Div Neurosurg, San Diego, CA 92103 USA
[4] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA
来源
PLOS ONE | 2013年 / 8卷 / 09期
基金
美国国家卫生研究院;
关键词
NF-KAPPA-B; DOUBLE-STRAND BREAKS; MULTIPLE-MYELOMA; MAMMALIAN-CELLS; GENE-EXPRESSION; SOLID TUMORS; BORTEZOMIB; ADENOCARCINOMA; RECOMBINATION; CHEMOTHERAPY;
D O I
10.1371/journal.pone.0073710
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Despite optimal radiation therapy (RT), chemotherapy and/or surgery, a majority of patients with locally advanced non-small cell lung cancer (NSCLC) fail treatment. To identify novel gene targets for improved tumor control, we performed whole genome RNAi screens to identify knockdowns that most reproducibly increase NSCLC cytotoxicity. These screens identified several proteasome subunits among top hits, including the topmost hit PSMA1, a component of the core 20 S proteasome. Radiation and proteasome inhibition showed synergistic effects. Proteasome inhibition resulted in an 80-90% decrease in homologous recombination (HR), a 50% decrease in expression of NF-kappa B-inducible HR genes BRCA1 and FANCD2, and a reduction of BRCA1, FANCD2 and RAD51 ionizing radiation-induced foci. I kappa B alpha RNAi knockdown rescued NSCLC radioresistance. Irradiation of mice with NCI-H460 xenografts after inducible PSMA1 shRNA knockdown markedly increased murine survival compared to either treatment alone. Proteasome inhibition is a promising strategy for NSCLC radiosensitization via inhibition of NF-kappa B-mediated expression of Fanconi Anemia/HR DNA repair genes.
引用
收藏
页数:14
相关论文
共 50 条
  • [31] Combinations of proteasome inhibitors with obatoclax are effective for small cell lung cancer
    Yan-ping Yin
    Wen-hao Shi
    Ke Deng
    Xiao-li Liu
    Hong Li
    Xiao-tong Lv
    Vivian Wai Yan Lui
    Chen Ding
    Bo Hong
    Wen-chu Lin
    Acta Pharmacologica Sinica, 2021, 42 : 1298 - 1310
  • [32] Combinations of proteasome inhibitors with obatoclax are effective for small cell lung cancer
    Yin, Yan-ping
    Shi, Wen-hao
    Deng, Ke
    Liu, Xiao-li
    Li, Hong
    Lv, Xiao-tong
    Lui, Vivian Wai Yan
    Ding, Chen
    Hong, Bo
    Lin, Wen-chu
    ACTA PHARMACOLOGICA SINICA, 2021, 42 (08) : 1298 - 1310
  • [33] A Predictive Model for Personalized Therapeutic Interventions in Non-small Cell Lung Cancer
    Kureshi, Nelofar
    Abidi, Syed Sibte Raza
    Blouin, Christian
    IEEE JOURNAL OF BIOMEDICAL AND HEALTH INFORMATICS, 2016, 20 (01) : 424 - 431
  • [34] Gefitinib in non-small cell lung cancer
    Tamura, K
    Fukuoka, M
    EXPERT OPINION ON PHARMACOTHERAPY, 2005, 6 (06) : 985 - 993
  • [35] Treatment of non-small cell lung cancer
    Reinmuth, N.
    Heigener, D.
    Reck, M.
    INTERNIST, 2011, 52 (12): : 1414 - 1421
  • [36] Paclitaxel for non-small cell lung cancer
    Ramalingam, S
    Belani, CP
    EXPERT OPINION ON PHARMACOTHERAPY, 2004, 5 (08) : 1771 - 1780
  • [37] Docetaxel and non-small cell lung cancer
    Le Guen, Y
    Le Cesne, A
    BULLETIN DU CANCER, 2004, 91 (03) : 263 - 270
  • [38] Chemotherapy in Non-Small Cell Lung Cancer
    Christopher J. Sweeney
    Alan B. Sandler
    Investigational New Drugs, 2000, 18 : 157 - 186
  • [39] Anthacyclines in non-small cell lung cancer
    Pronzato, P
    Vigani, A
    Tognoni, A
    Vaira, F
    Canessa, P
    LUNG CANCER, 2001, 34 : S57 - S59
  • [40] Immunotherapy for non-small cell lung cancer
    Kagamu, Hiroshi
    RESPIRATORY INVESTIGATION, 2024, 62 (02) : 307 - 312